Are There Any Limitations to Rapamycin's Use in Cancer Treatment?
Despite its potential, rapamycin is not a one-size-fits-all solution. Some tumors develop resistance to rapamycin by activating alternative pathways or through mutations in the mTOR pathway. Additionally, the drug's immunosuppressive effects can sometimes counteract its anticancer benefits. These limitations underscore the importance of personalized medicine and the need for ongoing research to identify biomarkers that can predict a patient's response to rapamycin.
